Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences is well-positioned to transform human health through its innovative RNA medicines platform, PRISM, which combines multiple modalities and deep insights into human genetics to treat rare and prevalent diseases. The upcoming FDA accelerated approval pathway decision and Phase 2a trial initiation for its obesity drug candidate, combined with positive clinical data from synthetic chemistry platform and KOL endorsement, provides a strong investment thesis for the stock. Additionally, the company's focus on targeting specific pathways with its oligonucleotide drugs, such as inhibiting Activin E for weight loss, sets it apart from competitors and offers potential for future success.

Bears say

WAVE Life Sciences is facing intense competition in the RNA medicines market with Sanofi's efdoralprin alfa Phase 2 showing favorable biomarker results and holding a regulatory lead. Additionally, the company's key programs for rare diseases, including alpha-1 antitrypsin deficiency and Huntington's disease, may face challenges in differentiating themselves from competitors in terms of clinical significance and addressing hepatic safety concerns. This, along with potential delays in the company's development roadmap, could hinder its commercial success and lead to a negative outlook for its stock.

WVE has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 14 analysts, WVE has a Buy consensus rating as of Jun 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.